Background: There is a lot of disagreement on the connection between metabolic syndrome and psoriasis. A
membrane-bound metallopeptidase with a wide variety of physiological uses is neprilysin (NEP). New information
suggests that NEP may contribute to the aetiology of the metabolic syndrome.
Objective: To evaluate serum NEP levels and their significance in the metabolic features of psoriasis patients.
Patients and Methods: A total of fifty psoriasis patients and thirty healthy volunteers of matched age and sex
participated in this case-control research. Every participant underwent clinical examination with focus on measuring
the PASI score, blood pressure (systolic, SBP and diastolic, DBP), and abdominal circumference. Additionally, lipid
profile, NEP, and fasting blood sugar (FBS) assays were performed.
Results: In comparison to controls, psoriasis patients had significantly higher SBP, DBP, FBS, and triglycerides
(p=0.01, 0.04, 0.04, and 0.01, respectively). Median level of NEP was 225.35pg/mL with range of 45.4-540.2pg/mL in
psoriasis patients compared with controls (51.65, 41.6-368.9) (p |
